64328-64-9

Upstream product

• 67399-84-2 4-heptyloxybenzoic acid methyl ester 
• 154845-73-5 4-heptyloxy-benzoic acid ethyl ester 
• 15872-42-1 4-heptyloxybenzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 120-47-8 Ethyl 4-hydroxybenzoate 

Downstream Products

• 165682-13-3 5-(p-n-heptyloxy)phenyl-3H-1,3,4-oxadiazoline-2-thione 
• 1240520-24-4 4-decyloxybenzoic acid N-4-(heptyloxy)benzoyl hydrazide 
• 1630012-45-1 C₁₅H₂₀N₂O₃ 
• 1443788-98-4 C₃₅H₄₁N₃O₅ 
• 1630012-59-7 C₁₉H₃₁N₃O₃ 
• 1630013-03-4 4-butyl-5-(4-heptyloxyphenyl)-2H-1,2,4-triazole-3(4H)-one 
• 1443791-90-9 (S)-methyl 2-(4-(tert-butyl)benzamido)-3-(4-(2-(4-(heptyloxy)benzoyl)hydrazine-carbonyl)phenyl)propanoate 
• 1443792-32-2 6-(4-bromophenyl)-3-(4-(heptyloxy)phenyl)-1,2,4-triazine 
• 77477-41-9 2-<4-Heptyloxy-phenyl>-5-<4-nonyloxy-phenyl>-1,3,4-thiadiazol 
• 77477-39-5 2-<4-Heptyloxy-phenyl>-5-<4-decyl-phenyl>-1,3,4-thiadiazol 
• 77477-38-4 2-<4-Heptyloxy-phenyl>-5-<4-octyl-phenyl>-1,3,4-thiadiazol 
• 77477-37-3 2-<4-Heptyloxy-phenyl>-5-<4-hexyl-phenyl>-1,3,4-thiadiazol 
• 77477-36-2 2-<4-Heptyloxy-phenyl>-5-<4-ethyl-phenyl>-1,3,4-thiadiazol 
• 158098-89-6 N-[5-(4-Heptyloxy-phenyl)-[1,3,4]thiadiazol-2-yl]-acetamide 

Relevant academic research and scientific papers

1-substituted benzoyl-4-fatty acyl semicarbazide derivative, preparation method and application thereof as antibacterial agent

The invention belongs to the technical field of antibacterial agents, and relates to a 1-substituted benzoyl-4-fatty acyl semicarbazide derivative, a preparation method and application thereof as an antibacterial agent. The compound is shown in a formula

GLP-1 RECEPTOR MODULATORS

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "^^^^" represents either or both the R and S form of the compound) (I) where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Synthesis and anticonvulsant activity evaluation of 4-butyl-5-(4- alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones

A series of 4-butyl-5-(4-alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones (6a-6u) was designed and synthesized. The anticonvulsant effects and neurotoxicity of the compounds were evaluated with maximal electroshock test and rotarod test. Among the synthetic compounds, 4-butyl-5-(4-(2-fluorinebenzyl)phenyl)-2H-1,2,4- triazole-3 (4H)-one (6k) was the most potent with ED50 value of 27.4 mg/kg and protective index (PI = TD50/ED50) value of 12.0. Besides the anti-MES efficacy, the potency of compound 6k against seizures induced by pentylenetetrazole (PTZ), 3-mercaptopropionic acid (3-MP), and bicuculline (BIC) was also established, which suggested that the mechanisms of action including enhancing of GABAergic activity might be involved in its anticonvulsant activity.

NOVEL GLP-1 RECEPTOR MODULATORS

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "()" represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

NOVEL GLP-1 RECEPTOR MODULATORS

The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where"﹋" represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

Synthesis and gelation behavior of 4′-propyl-1,1′- bi(cyclohexyl)-4-one 4-alkoxybenzoylhydrazone

A series of new alkoxybenzoylhydrazones of 4′-propyl-1,1′- bi(cyclohexyl)-4-one were prepared as novel low molecular weight organogelators (LMOGs). Their gelation behaviors in 10 solvents were tested. Some of the compounds could form stable gels in bulk o

Synthesis and characterization of 1,3,4-oxadiazole derivatives containing alkoxy chains with different lengths

The synthesis, optical properties, electrochemical properties, electronic structures and applications in electroluminescent device of three series of 1,3,4-oxadiazole derivatives, 1,4-bis[(4-methylphenyl)-1,3,4-oxadiazolyl]phenylene (OXD1), 5,5′-di-(4-methyl)-2,2′-p-(2,5-bisalkoxyphenylene)-bis-1,3,4 -oxadiazole (OXD2-n) and 1,4-bis[(4-alkoxyphenyl)-1,3,4-oxadiazolyl]phenylene (OXD3-n) are reported. The molecular structures of the oxadiazole compounds were confirmed by FT-IR, 1H NMR spectroscopy and elemental analysis. The optical and electrochemical properties of the compounds were investigated by UV-vis absorption and photoluminescence spectroscopy as well as cyclic voltammetry. The results show that introduction of two alkoxy groups whose electron-donating ability is stronger than that of methyl groups increases the electron density of the conjugated segment of OXD2-n (with side-on alkoxy substituents) and OXD3-n (with end-on alkoxy substituents), and thus leads to the absorption maximum bathochromic-shift compared to that of OXD1. The HOMO and LUMO energy levels of the compounds studied are in the range of -2.78 to -2.89 and -5.75 to -6.20 eV. Calculations on the representative compounds by the Dmol3 package of MS Modeling 3.0 revealed that the increase of energy levels in both OXD2-n and OXD3-n was due to the change of the frontier molecular orbital distribution in the central benzene ring. The light-emitting devices have been fabricated using blends of MEH-PPV and these compounds as emissive layers, among which, maximum brightness up to 11810 cd m-2 (8.5 V) has been observed, which is 40 times brighter than that with MEH-PPV. The result of the devices suggested that oxadiazole derivatives studied function well as electron-transporting materials and can be used in LEDs, and thus to enhance the efficiency of LEDs.

Synthesis and mesomorphic properties of azo compounds derived from phenyl- and thienyl-1,3,4-thiadiazole

The synthesis and mesomorphic behaviour of new series of liquid crystals containing 1,3,4-thiadiazole and thiophene rings with azo central bond are reported (series 5a and 5b). All compounds of series 5a exhibit enantiotropic nematic mesophase and the hig